Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Clin Pharmacol Ther ; 48(10): 670-7, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20875373

ABSTRACT

OBJECTIVES: Polyisoprenylated acylphloroglucinols have recently emerged as antitumoral agents. This study aims at elucidating the antiretroviral activity of two such compounds which were isolated from Caribbean propolis: 7-epi-nemorosone and plukenetione A, the structure of which is based on an adamantane moiety. Plukenetione A is for the first time shown to have antiretroviral activity. MATERIAL AND METHODS: The isolation of both small molecules was carried out using RP-HPLC. Their antiretroviral activity was studied based on lentiviral particles produced in HEK293T cells from the SIV-based vector VLDBH; their cytotoxicity was monitored by MTT proliferation assay. The antiviral activity of 7-epi-nemorosone was studied in CEMx174-SEAP infected with the HIV-1-strain pNL4.3wt. Reverse transcriptase inhibition was determined by a standard two-step RT-PCR using MMLV RT. RESULTS: 7-epi-nemorosone and plukenetione A were found to be potent antilentiviral agents in the employed system, inhibiting viral infection at concentrations below 1 µM/2 µM, respectively. Whereas 7-epi-nemorosone was not able to inhibit the reverse transcriptase in vitro (IC50 > 25 µM), plukenetione A effectively inhibited its enzymatic activity at an IC50 of 1.75 µM. CONCLUSIONS: Despite 7-epi-nemorosone and plukenetione A sharing some structural core elements, the mechanism of action involved in their antiretroviral activity seems to be different. We propose that 7-epi-nemorosone inhibits the viral replication by interrupting the Akt/PKB signaling cascade, as was demonstrated previously in various cell lines. Since plukenetione A effectively inhibits the enzymatic activity of MMLV reverse transcriptase at concentrations that show antilentiviral activity, we suggest that this small molecule acts by interfering with the enzyme's catalytic site.


Subject(s)
Antiviral Agents/pharmacology , Benzophenones/pharmacology , Lentivirus/drug effects , Polycyclic Compounds/pharmacology , Propolis/chemistry , Benzophenones/chemistry , Caribbean Region , Cells, Cultured , HIV-1/drug effects , Humans , Polycyclic Compounds/chemistry
2.
J Acquir Immune Defic Syndr (1988) ; 6(3): 227-30, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8450395

ABSTRACT

The promoter of the human gene encoding the p65 subunit of the transcription factor NF-kappa B was cloned and the nucleotide sequence determined. The p65 promoter lacks both TATA and CCAAT consensus sequences. The p65 promoter contains three consensus binding sites of the transcription factor SP1. In contrast to the promoter of the p50 subunit of NF-kappa B, no sequences predicted to bind NF-kappa B are present in the p65 promoter. Phorbol ester (PMA) and phytohemagglutinin (PHA) treatment of Jurkat cells did not activate the p65 promoter in transient transfection experiments. Using different deletion mutants of the p65 promoter, essential promoter elements were mapped.


Subject(s)
NF-kappa B/chemistry , Base Sequence , Binding Sites , Chloramphenicol O-Acetyltransferase/biosynthesis , Chloramphenicol O-Acetyltransferase/genetics , Consensus Sequence , Enzyme Activation/drug effects , Humans , Leukemia, T-Cell , Molecular Sequence Data , NF-kappa B/drug effects , NF-kappa B/genetics , NF-kappa B/metabolism , NF-kappa B p50 Subunit , Phytohemagglutinins/pharmacology , Protein Precursors/chemistry , Protein Precursors/drug effects , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factor RelA , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...